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Sudden cardiac death (SCD) is defined as death from cardiac causes occurring unexpectedly 
within 1 hour of onset of symptoms. About 80% of SCDs are due to ventricular 
tachyarrhythmia that is, ventricular tachycardia and ventricular fibrillation. The remaining 
20% consists of a number of conditions, including cardiomyopathies (10–15%), other 
structural heart defects (less than 5%) and bradycardia. SCD is responsible for more deaths 
than cancer, stroke, and AIDS combined (CDC, 2002). The overall incidence of SCD in the 
United States and Europe is 1 to 2 per 1000 people (0.1% to 0.2%) annually. Almost 80% of 
all SCDs occur at home. The 10%-25% survival rate is low and has not been improved by the 
automatic external defibrillator in patients with moderate risk (de Vreede-Swagemakers, 
1997; Bardy, 2008; Myerburg, 2001). On the other hand, several clinical trials showed that the 
implantable cardioverter defibrillator (ICD) could prevent SCD and reduce overall mortality 
in some patients with severe left ventrocular dysfunction. For these reasons, ICD therapy 
has become the first choice strategy to prevent SCD from malignant ventricular 
tachyarrhythmia in high-risk patients. However, there are numerous well-recognized 
limitations to ICD therapy. These include the effects and the result of appropriate and 
inappropriate ICD shocks, the cost of the devices, complications related both to the 
implantation procedure and to subsequent device function, device malfunction, and 
restricted efficacy despite normal device function in presence of significant concomitant 
disease and in particular in presence of severe left ventricular disfunction. Several possible 
solutions have been proposed in the clinical practice, these include better patients’ selection 
for ICD implantation, better ICD programmation, better medical therapy and arrhythmic 
substrate ablation.  The role of catheter ablation of ventricular tachycardia in patients with 
structural heart disease has been increasing in the last 2 decades. The mechanisms of 
ventricular tachycardia are now clearer, and the electroanatomic mapping systems have 
made precise activation and substrate mapping more feasible; therefore, the potential for 
doing catheter ablation of ventricular tachycardia has increased dramatically in the past 
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several years. Now, multiple and/or unstable ventricular tachycardias, polymorphic 
ventricular tachycardias, and ventricular fibrillation in selected cases can be targeted by 
different ablation strategies (Raymond, 2009). General recommendations for the use of 
catheter ablation are well documented; at this time, an open question remains, namely, 
whether catheter ablation can replace ICD in patients with structural heart disease. 
2. Implantable cardioverter defibrillator 
In 1980 Mirowski and colleagues (Mirowski, 1980) implanted the first ICD in a young female 
with recurrent ventricular fibrillation and provided an innovative approach to aborted SCD. 
This milestone event started a prolific period of research in SCD prevention and therapy. 
Although the ICD was considered a treatment of last resort during that incipient stage, 
subsequent years have witnessed expansion of indications for ICD implantation. (Epstein, 
2008). Several large-scale clinical trials have demonstred its efficacy for both primary and 
secondary prevention of SCD in patients with ischemic and nonischemic cardiomyopathy. 
The advent of transvenous ICD technology and their potential effects in prevention of SCD 
elicited also several trials to compare the ICD with conventional antiarrhythmic drug 
therapy alone. In such high-risk patients, ICD therapy has been shown to improve survival 
rate compared with a neutral or harmful effect of chronic pharmacological therapy 
(Dimarco, 2003; Reiffel, 2005). In light of these excellent results, the number of ICD 
implantations has increased significantly in the last decade, with a simultaneous reduction 
of the use of stand-alone antiarrhythmic drugs for ventricular indications. (Al-Khatib, 2003; 
Hine, 1989; Zhan, 2008). 
2.1 ICD-related complications 
Because of the growing number of ICD patients, ICD-related problems are increasingly 
encountered and patients undergoing one or multiple shocks are today frequently seen in 
emergency departments, hospital wards, or ICD clinics. 
Therefore, personnel working in these environments should have specific knowledge 
concerning the management of ICD-related problems. Typically, patients who receive ICDs 
are at high risk for recurrent arrhythmia; hence, most patients receive one or more ICD 
treatments for spontaneous arrhythmias after implantation (Dimarco, 2003). Despite the 
technological evolution of ICD systems, more than 20% of shocks are triggered by 
supraventricular arrhythmia; thus, they are inappropriate (Dorian, 2004; Nanthakumar, 
2000; Rosenqvist, 1998). 
The most common cause of inappropriate ICD shocks was atrial fibrillation (44%), followed 
by other supraventricular tachycardias, including sinus tachycardia (36%), and abnormal 
sensing (20%) (Daubert, 2008). If appropriate ICD shocks save lives, it may emerge that a 
few inappropriate shocks are a small price to pay (Raitt, 2008). Inappropriate shocks have a 
downside. There is a growing medical literature on the adverse psychological consequences 
of ICD shocks, whether appropriate or not. The ICD shocks are perceived as awfully 
painful. After an ICD shock, the patient may become immobilized, fearing that any 
movement or activity might activate another shock. Multiple shocks are the most 
frightening for patients, causing them to wonder if the device is really working or if it might 
even kill them. Those individuals who experience an ICD shock exhibit higher levels of 
psychological distress, anxiety, anger, and depression than those who do not. (Ahmad, 2000; 
Dunbar, 1993; Dougherty, 1995). The ICD shocks lead to greater psychological distress for 
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family members as well (Luderitz, 1994). Anxiety after ICD shocks remains elevated for an 
unknown amount of time, and then begins to return to normal levels as long as no further 
shocks take place (Fricchione, 1989). The level of anxiety, depression, and poor quality of life 
is comparable in incidence to patients resuscitated from cardiac arrest and cardiopulmonary 
bypass surgery (Bostwick, 2007). In addition, ICD implantation is associated with 
neuropsychological impairment that significantly affects acute and long-term cognitive 
function (Hallas, 2010). 
2.2 Electrical storm 
Another significant problem is the electrical storm, which is defined as having more than three 
shocks in a 24-hours period, occurring in 10% to 20% of patients during the first 2 years after 
ICD implantation (Exner, 2001; Dunbar, 1999). An electrical storm establishes an adverse 
conditioned response including avoidance of activities that may have been associated with the 
shocks, leading to heightened self-monitoring of bodily functions, increased anxiety, 
uncertainty, and increased dependence. In some ICD patients, this condition leads to a reactive 
depression, helplessness, and post-traumatic stress disorder. In addition, an electrical storm is 
associated with increased mortality (Credner, 1998; Arya, 2006). 
2.3 Mortality in patients with ICD 
Inappropriate ICD shocks may not only have adverse psychological consequences but also 
adverse medical consequences, such as a higher mortality than patients who did not suffer 
inappropriate shocks, with a hazard ratio of 2.29 (p=0.025) (Daubert & Zareba, 2008). 
Similarly, patients with appropriate shocks also had an increased overall mortality with a 
hazard ratio between 3 and 4. The higher hazard ratio arises in patients who had both 
appropriate and inappropriate shocks. In a multivariate analysis, predictors of inappropriate 
shocks included age > 70 years (hazard ratio 1.9, 95% CI 1.3-2.5; p=0.01) and history of atrial 
fibrillation (hazard ratio 2.0, 95% CI 1.5-2.7; p<0.01). The occurrence of only one 
inappropriate shock showed an all-cause mortality hazard ratio of 1.6 (95% CI 1.1-2.3; 
p=0.01), adjusted for history of atrial fibrillation, age, NYHA functional class, renal function, 
QRS duration, and beta-blockers use. Each additional inappropriate shock corresponded to 
a hazard ratio of 1.4 (95% CI 1.2-1.7; p=0.01), such that the risk was more than triple after a 
total of five such shocks (Johannes, 2011). It is interesting to investigate the causality 
between ICD shocks and an increased risk of death. It is especially reasonable to postulate 
that patients with progressive heart failure, and therefore increased mortality, might be 
more likely to develop atrial fibrillation and to suffer inappropriate ICD shocks. These same 
patients may also be more likely to exhibit ventricular tachycardia or ventricular fibrillation 
induced by progressive congestive heart failure and to undergo appropriate ICD shocks 
before dying of congestive heart failure. Depending on the ventricular rate and ICD 
programming, atrial fibrillation and sinus tachycardia can lead to antitachycardia pacing 
instead of ICD shocks. If rapid atrial fibrillation and sinus tachycardia were markers for 
increased mortality, then one would expect inappropriate antitachycardia pacing to be 
associated with increased mortality as well. In contrast to this expectation, in the MADIT II 
population, although both appropriate and inappropriate shocks were associated with an 
increased total mortality, appropriate and inappropriate antitachycardia pacing was not. In 
fact, having only antitachycardia pacing episodes and no shocks was associated with a trend 
toward lower mortality. Various likely contributions of ICD shocks to increased total 
mortality might subsist. Several possible explanations are debated. The first explanation is a 
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direct damage on the myocardium. Animal models have demonstrated a vast array of 
potentially deleterious effects of DC shocks including alterations in cellular morphology, 
biochemical function, electrophysiologic function, and hemodynamic function (Tedeschi, 
1954; Van Vleet, 1977; Babbs, 1980; Jones, 1980; Wilson, 1988; Trouton, 1992). 
Many of the morphologic, biochemical, electrophysiologic and hemodynamic adverse 
effects of high-intensity DC shocks reported in animals models have also been noted, 
although with lower frequency, in patients who have received DC shocks of clinically 
significant intensities. As in animal models, many of these functional changes have been 
demonstrated to last for minutes to hours as opposed to seconds. The immediacy of post-
shock electromechanical dissociation suggests that necrosis is not the cause of the 
phenomenon. Instead, it is likely that an instantaneous functional abnormality is 
accountable for electromechanical dissociation. This probability is supported by reports of 
severe hemodynamic deterioration after internal DC shocks during ICD implantation 
procedures (Avitall, 1990; Steinbeck, 1994). A severe manifestation of this phenomenon 
could be expressed as sudden death due to electromechanical dissociation that is the most 
common mechanism of sudden death in patients with a functioning ICD in place and is 
associated with high-energy shocks in patients with advanced congestive heart failure. 
(Mitchell, 2002). The protection afforded by the ICD against sudden arrhythmic death is not 
absolute, being the rate of sudden death among patients with ICD approximately 5%. If the 
majority of patients receiving ICDs is similar to those patients included in randomized 
clinical trials, then ICDs can be expected to be 60 to 70% effective in reducing SCD. This may 
be more effective than any other available therapy and is thought to be additive to reduction 
of SCD due to other therapies such as beta-blockers and angiotensin converting enzyme 
inhibitors. On the other hand, it should serve as a reminder to physicians of the importance 
of optimization of ICD programming and medical therapy and to patients with regard to 
compliance with medications and recommended life-style modifications as these measures 
will reduce their risk (Anderson, 2005). 
The second explanation is a possible non-direct damage on the myocardium for the adverse 
effects of ICD shocks that could direct to increased mortality. We have already outlined the 
adverse psychological effects of ICD shocks, anxiety and depression, that can set off a 
cascade of events, including poor compliance to medical therapy, that culminates in an 
increased risk of death in patients with congestive heart failure. Whether or not there is a 
causal relationship between ICD shocks and the associated increase in mortality, the 
psychological effects of shocks alone are reason to do everything possible to reduce the 
incidence of appropriate and inappropriate shocks (Raitt, 2008). 
The extensive implementation of ICD therapy has changed the natural history of ventricular 
tachycardia (Mason, 1993; Connolly, 2000; AVID Investigators, 1997). 
2.4 Approaches to reduce ICD therapy 
CDs effectively terminate ventricular arrhythmias through either antitachycardia pacing or 
shocks and comprise the standard of care for patients at high risk for ventricular 
arrhythmias. However, ICDs do not prevent the occurrence of ventricular arrhythmias. 
Patients who, formerly, would have suffered sudden death, now survive to experience 
recurrent ventricular tachycardia and ICD therapy; thus, shock delivery is administered in a 
large proportion to patients who have experienced at least one ventricular arrhythmia 
(Connolly, 2006; Credner, 1998). 
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2.4.1 Patients selection 
There are different approaches to reduce the incidence of appropriate and inappropriate 
shocks. The first line of defense is good patients’ selection for ICD implantation. There is a 
well-documented increased complication rate for non-guideline-based ICD implantation. In 
particular, there was an excess of 4 deaths per 1000 ICD implants when the device was 
implanted outside the guidelines. (Kadish, 2011). The age at implant of patients is very 
important. Indeed in elderly patients, pooled analysis of the 3 trials considered most 
relevant to current use of ICDs for primary prevention (MADIT-II, DEFINITE, and SCD-
HeFT) showed that prophylactic ICD therapy was associated with a nonsignificant 
reduction in all-cause mortality compared with medical therapy (HR, 0.81 [95% CI, 0.62 to 
1.05]; P =0.11). Analyses that included the 2 studies of early enrolled post-acute myocardial 
infarction patients (DINAMIT and IRIS), also showed no statistically significant decrease in 
mortality with prophylactic ICD therapy (HR, 0.97 [CI, 0.78 to 1.19]; P=0.75) (Santangeli, 
2010). Patients who received a non–evidence-based ICD had significantly more 
comorbidities than patients who received an evidence-based device and were at a higher 
risk of postprocedural complications (including death). The increased prevalence of 
comorbidities in recipients of non–evidence based ICDs is unquestionably associated with 
an increased risk of competing causes of death (Al-Khatib, 2011). While a small risk of 
complications is acceptable when a procedure has been shown to improve outcomes, no risk 
is acceptable if a procedure has no demonstrated benefit.  
2.4.2 ICD programmation 
The second line of defense is ICD programming. In the MADIT II trial, AF was the most 
common cause of inappropriate shocks. The patients provided with the stability detection 
algorithm programmed on in their ICDs, which is designed to prevent shocks for atrial 
fibrillation, were less likely to have inappropriate shocks (Daubert, 2008).  Other detection 
algorithms are available on many ICDs that evaluate the morphology of tachycardias or the 
timing and frequency of atrial and ventricular activation. They prevent inappropriate shocks 
for supraventricular rhythms such as atrial fibrillation and sinus tachycardia. These 
algorithms help to prevent inappropriate shocks. The next step in reducing ICD shocks is 
programming the devices to use antitachycardia pacing instead of shocks whenever 
possible. Currently, many electrophysiologists do not routinely program antitachycardia 
pacing in patients with ICDs. By protocol, antitachycardia pacing was not enabled in the 
SCD-HeFT (Bardy, 2005). Arguing in favor of the usefulness and efficacy of antitachycardia 
pacing is the Pain Free II study, which showed that aggressive use of antitachycardia 
pacing, even for very fast episodes of ventricular tachycardia, was effective and reduced the 
risk of shocks (Wathen, 2004). Some physicians are concerned that an ineffective 
antitachycardia pacing will delay tachycardia termination. In response to this concern, one 
ICD manufacturer has introduced a characteristic in which antitachycardia pacing is used to 
try to terminate ventricular arrhythmias while the capacitor is charging in preparation for an 
ICD shock. If the antitachycardia pacing works, the shock is aborted; otherwise, the shock 
delivery is not delayed. Given the adverse psychological effects of ICD shocks and the 
possibility that shocks may increase mortality, these programming features should probably 
be used whenever possible (Raitt, 2008). 
2.4.3 Medical therapy 
It is less clear whether medical therapy can reduce the risk of ICD shocks. If, in fact, 
exacerbation of congestive heart failure leads to ICD shocks, perhaps, more aggressive  
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congestive heart failure treatment in patients with ICDs, and use of congestive heart failure 
monitoring protocols built into some ICDs might prevent some appropriate and 
inappropriate shocks. It is less clear whether empiric antiarrhythmic therapy prevents ICD 
shocks; in addition, such therapy cannot be recommended at this time because of the risk of 
proarrhythmia and the cardiac and noncardiac side effects of antiarrhythmic medications 
(Raitt, 2008). Beyond aggressive treatment of ischemia and heart failure, preventive 
treatments for inhibition of ventricular tachycardia are limited. Three agents have been 
demonstrated in randomized clinical trials to reduce ICD therapies. Amiodarone resulted in 
a substantial decline in ICD shocks compared with beta-blockers in patients who had 
experienced prior ventricular arrhythmias. Sotalol moderately reduced shocks (after a 3-
week blanking period) in the same population and increased shock-free survival in a 
placebo-controlled trial (Raitt, 2008). Azimilide has been found to reduce all-cause shocks 
and symptomatic ventricular tachycardia in a placebo-controlled study (Dorian, 2004). 
Unfortunately, each of these agents carries significant risk of harmful side-effects. The 
proarrhythmic mortality risk of sotalol (Waldo, 1996) may be both attenuated in ICD 
patients, and may be increased in presence of heart failure, diuretic use and older age – all 
common features of patients with ischemic cardiomyopathy and ventricular tachycardia. 
Amiodarone use is also associated with a high incidence of adverse effects (Brendorp, 2002), 
which are moderate at low doses (Vorperian, 1997); on the other hand, they increase with 
dose and duration such that, in long-term use, side-effects or recurrent arrhythmia are seen 
very frequently (Bokhari, 2004). Amiodarone use, nephropathy, low left ventricular ejection 
fraction, and supraventricular tachycardia are independent predictors of cardiac death 
(Worck, 2007). One can speculate that proarrhythmia and/or increased defibrillation 
thresholds could play a role in the association with increased mortality (Khalighi, 1997; 
Zhou, 1998). In addition, amiodarone harmfully affected survival in NYHA III patients in 
the SCD-HeFT (Bardy, 2005). Azimilide has not demonstrated a change in mortality and is 
associated with a relatively low rate of torsades de pointes (Camm, 2004; Pratt, 2006), but 
has not been made available for clinical use. Dronedarone has been associated with higher 
mortality in the situation of heart failure. Other antiarrhythmic drugs, including 
dronedarone and dofetilide, have been disappointing, hence, nonpharmacologic alternatives 
are needed. (Echt, 1991; The CAST Investigators, 1989; DIAMOND studies, 1997; Torp-
Pedersen, 1999; Kober, 2008). A good therapeutic alternative to reduce risk of ICD shocks is 
catheter ablation of ventricular tachycardias. 
3. Catheter ablation 
In 1987, catheter ablation of ventricular tachycardia was a newly emerging field. The 
primary therapy for drug refractory ventricular tachycardia was surgical ablation, which 
was successful in controlling this arrhythmia in 80% to 90% of selected patients, but yielded 
an operative mortality of 5% to 15% (Cox, 1989). Over the subsequent two decades, 
significant developments in ablation and mapping technology contributed to improved 
outcomes: catheter ablation, first, using direct-current energy and radiofrequency current, 
later. The initial acute success rates using radiofrequency current were on average 75%, with 
a recurrence rate of 21% over a follow-up time average of 21 months (Gu¨rsoy, 1993; 
Stevenson, 1993; Gonska, 1994; Kim, 1994; Wilber, 1995; Stevenson, 1998). The limitation of 
catheter ablation at this time was 2-fold. First, only conventional radiofrequency current 
(non-irrigated) was available; secondly, only patients with hemodynamically tolerated and 
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stable ventricular tachycardia could be treated, for which an ECG of the spontaneous 
ventricular tachycardia had been obtained and mapping could be performed during such 
event (Bogun, 2006; de Chillou, 2002). 
3.1 Electroanatomic systems and substrate mapping 
The introduction of the electroanatomic mapping system allowed creation of ventricular 
geometry and displayed low-voltage areas of scar or infarction (Marchlinski, 2000). 
Mapping during stable sinus or paced rhythm to identify targets for ventricular tachycardia, 
the so-called substrate mapping (Reddy, 2003; Volkmer, 2006), allows performing catheter 
ablation in patients with unstable, hemodynamically nontolerated ventricular tachycardia, 
in patients with multiple ventricular tachycardias, or in patients without inducible 
ventricular tachycardia (Figure 1). 
 
 
Fig. 1. A and B show the substrate respectively, in the posterior and inferior view in a 
patient with ischemic dilated cardiomiopathy. In substrate mapping the scar region (grey 
area) was defined as areas with bipolar local electrogram ≤0.5 mV and the normal 
myocardium (purple area) was defined as areas with a bipolar local electrogram ≥1.5 mV. 
The white dots represent the ablation lesions. 
Today, most patients with recurrent ventricular tachycardia have an ICD that promptly 
terminates ventricular tachycardia, so its hemodynamic impact and ECG morphology are 
often unknown. Thus, substrate mapping is often the only method to perform catheter 
ablation in patients with an ICD (Kuck, 2009). By selecting catheter ablation for an 
individual patient, risks and benefits that are determined by patient characteristics, as well  
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as the availability of appropriate facilities with technical expertise should be considered. In 
the past, catheter ablation of ventricular tachycardia has often been considered a procedure 
of last resort; now, a recent consensus document has suggested that catheter ablation should 
generally be considered early in the treatment of patients with recurrent ventricular 
tachycardia, recognizing that ventricular tachycardia was based mostly upon uncontrolled 
cohort studies and single-center reports. In the setting of high-risk patients with ICDs, 
catheter ablation of ventricular tachycardia has been proven to decrease the number of 
shocks. 
3.1.1 Catheter ablation in ischemic patients 
In most studies, catheter ablation has been performed in patients with ischemic heart 
disease after multiple ICD interventions, including patients with incessant ventricular 
tachycardia. In almost all of these studies, patients were included after failure of 1 or 
multiple antiarrhythmic drugs. The second largest prospective multicenter trials conducted 
in the United States using irrigated radiofrequency current included more than 350 patients 
with structural heart disease, predominantly coronary artery disease (Calkins, 2000; 
Stevenson, 2008). Both studies differ with respect to patient inclusion and to 
electrophysiological end-points, but the results were similar. In the cooled radiofrequency 
current trial, the acute success rate was 71% when the end-point was the elimination of all 
mappable ventricular tachycardias and 41% when the end-point was the elimination of 
ventricular tachycardia of any kind. In the thermocool trial, the acute success rate was 49% 
when elimination of all inducible ventricular tachycardia was used as the end-point. The 
Kaplan–Meier recurrence rate of sustained ventricular arrhythmia was 56% during 1 year of 
follow-up. The thermocool trial limited the follow-up time to 6 months for the efficacy end-
point. Independence from ventricular tachycardia was 53%. In the thermocool trial, the 
frequency of ventricular tachycardia was reduced by ≥75% in 67% of patients. An increase in 
the number of ventricular tachycardia episodes was observed in 20% of patients. Patients 
with ventricular tachycardia recurrences were older, had more heart failure, more atrial 
fibrillation, multiple myocardial infarction sites, and more inducible ventricular 
tachycardias; they received more radiofrequency lesions, and more often, had a ventricular 
tachycardia inducible after ablation compared with patients without ventricular tachycardia 
recurrences. In the cooled radiofrequency current study, a ≥75% reduction in the ventricular 
tachycardia frequency in the two months after ablation compared to the two months before 
ablation was observed in 99 of 122 patients (81%), of whom 115 had an ICD. Only the 
absence of an inducible ventricular tachycardia, recognized as the clinical ventricular 
tachycardia, was a predictor of clinical success. Another European multicenter study (Euro-
VT study) performed catheter ablation using external irrigation in 63 patients with recurrent 
scar-related ventricular tachycardia (Tanner, 2009). Catheter ablation was acutely successful 
in 51 patients (81%). During a mean follow-up of 12 ± 3 months, 31 patients (49%, 19 of 51 
initially successfully ablated patients and 12 of 12 unsuccessfully ablated patients) 
experienced ventricular tachycardia recurrence. However, even among the patients with 
recurrence, the number of ICD therapies was significantly reduced in 79% of the cases. One 
limitation of catheter ablation studies in ICD patients must be addressed. In almost all 
studies, antiarrhythmic drugs were not systematically withdrawn after ablation. Therefore, 
any beneficial effect of catheter ablation in these studies may be influenced by drug therapy, 
even when most patients were drug failures before ventricular tachycardia ablation. While 
the above-mentioned and previously conducted studies clearly showed the beneficial effect  
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of catheter ablation of ventricular tachycardia with respect to ventricular tachycardia 
recurrence, the periprocedural mortality should also be considered in these patients. Indeed, 
the effectiveness of catheter ablation in ICD patients must be balanced with the safety profile 
of this interventional procedure. The reported procedure-related mortality ranges from 0% 
to 3.5%. In addition, major complications including stroke, myocardial infarction, 
tamponade, valve injury, and atrio-ventricular block occurred in 8-10% of the patients. In 
the Euro-VT study, the rate of major complications was only 1.6% and the 1-year mortality 
in these studies reached 8-18%. 
3.1.2 Catheter ablation in nonischemic patients 
Data on catheter ablation in ICD patients with nonischemic ventricular tachycardia from 
large multicenter trials are lacking. The anatomic substrate is different in patients with 
nonischemic ventricular tachycardia, since more extensive scar is often present in the 
epicardium and not in the endocardium, compared with the majority of patients with a 
previous myocardial infarct. In both groups, epicardial ablation has been successfully 
applied after failure of endocardial ablation. In general, acute success rates of catheter 
ablation are similar to ischemic ventricular tachycardia patients, but recurrence rates seem 
to be higher (Soejima, 2004; Delacretaz, 2000; Nazarian, 2005; Verma, 2005; Dalal, 2007).  
Moreover, catheter ablation has been shown to eliminate electrical storm in patients with 
and without underlying heart disease by either inhibiting the trigger factors for ventricular 
tachycardia/ventricular fibrillation, namely ventricular premature beats, or by modifying 
the substrate for ventricular tachycardia/ventricular fibrillation. Catheter ablation 
significantly reduces the number of ICD interventions in patients with electrical storm 
(Della Bella, 2004). In a recent single-center study, 95 patients with electrical storm, leading 
to a mean number of 14 ICD shocks per patient per day, underwent catheter ablation. 
Seventy-two patients had underlying coronary artery disease, 10 patients had dilated 
cardiomyopathy, and 13 patients had right ventricular disease. After catheter ablation, 
electrical storm was acutely suppressed in all patients and did not recur during follow-up of 
22 months in patients in whom either no ventricular tachycardia could be induced or clinical 
ventricular tachycardia became noninducible. Furthermore, death from any cause could 
significantly be reduced in both groups compared with patients in whom the clinical 
ventricular tachycardia remained inducible and electrical storm recurred. Both cardiac death 
as well as sudden cardiac death was significantly higher in patients with electrical storm 
recurrences (50% versus 0%). This observation indicates that a successful ventricular 
tachycardia ablation procedure may be associated with a reduction of total mortality in 
subgroups of patients. The procedure typically is prompted by frequent defibrillator 
therapies despite multiple combinations of antiarrhythmic drugs. Use of catheter ablation 
earlier during the clinical course of ventricular tachycardia, soon after its onset, may be 
beneficial. 
3.1.3 Prophylactic catheter ablation 
The role of prophylactic radiofrequency catheter ablation of arrhythmogenic substrate in 
patients with a previous myocardial infarction in preventing ICD therapy was evaluated in 
the Substrate Mapping and Ablation in Sinus Rhythm to Halt Ventricular Tachycardia 
(SMASH-VT) trial and in the Catheter ablation of stable ventricular tachycardia before 
defibrillator implantation in patients with coronary heart disease (VTACH) trial (Reddy, 
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2007; Kuck, 2010). SMASH-VT was a prospective randomized three-center trial of catheter 
ablation versus no intervention for patients with implantation of a secondary prophylactic 
ICD within the prior 6 months or who had received recent appropriate ICD therapy. 
Catheter ablation resulted in reduced appropriate ICD therapy from 33 to 12% (hazard ratio 
0.35). Secondary end-points included a reduction in ventricular tachycardia storm, but no 
effect on total mortality occurred. Although this landmark study demonstrated proof of the 
principle that catheter ablation can have a favorable effect, limitations such as the lack of 
adjudicator blinding, stratification and standard ICD programming make the results more 
difficult to interpret. Most importantly, the role of antiarrhythmic drugs was not addressed 
by this study design, limiting direct applicability of the results to clinical practice (El-
Damaty, & Sapp, 2011). VTACH trial was similar in design to that of SMASH-VT. One 
hundred and ten patients presenting with ventricular tachycardia and prior myocardial 
infarction were randomly allocated to catheter ablation or no intervention, followed by ICD 
implantation. Antiarrhythmic drug use was discouraged, and not significantly different 
between groups. Patients were stratified by center and ejection fraction (cut-off 30%); a 
blinded committee adjudicated outcomes and ICD programming was standardized. The 
VTACH trial showed that catheter ablation, performed before ICD implantation in patients 
after the first episode of a hemodynamically stable ventricular tachycardia, significantly 
prolonged the median time to first ventricular tachycardia/ventricular fibrillation from 5.9 
months to 18.6 months. The benefit was more pronounced in patients with left ventricular 
ejection fraction > 30% (Figure 2). 
 
 
Fig. 2. Survival free from ventricular tachycardia (VT) or ventricular fibrillation (VF) in 
patients with left-ventricular ejection fraction (LVEF) less or equal than 30% and left-
ventricular ejection fraction greater than 30%. 
Furthermore, catheter ablation reduced the overall incidence of appropriate ICD 
interventions by 28% and the incidence of ICD shocks by 43%. Even more importantly, 
catheter ablation reduced the median number of appropriate ICD interventions per patient 
and year of follow-up by 93%. In addition, catheter ablation significantly reduced the rate of 
hospitalizations for cardiac reasons. This well designed trial provides further support for the 
Modified from Kuck et al., Lancet, 2010 
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effectiveness of catheter ablation in reducing ventricular tachycardia events, but does not 
give clinical guidance on the relative role of catheter ablation in comparison to 
antiarrhythmic drug therapy. The complication rate becomes even more important if an 
interventional procedure is performed prophylactically. In both trials, the incidence of 
ablation related death was 0% and of major complications 4.7% and 3.8%, respectively. The 
event rate in the control group of the VTACH trial was roughly twice as that observed in 
SMASH-VT, but the relative reduction in events was similar, at 35–40%. 
3.2 Open questions in VT catheter ablation 
3.2.1 The role of antiarrhythmic therapy 
Many important questions remain. Should ablation be preferred over antiarrhythmic drugs? 
The largest prospective, randomized trial evaluating several drug regimen in patients with 
an ICD for secondary prevention showed that the combination of beta-blockers and 
amiodarone had the greatest effect, with a reduction of ICD shocks by 73% compared to the 
control group (beta-blocker alone) and of 57% compared to the sotalol group, with an 
incidence of ICD shocks in the control group of approximately 30% after 1 year (Connolly, SJ 
et al. 2006). In a previous trial, sotalol reduced the risk of death from any cause or the 
delivery of a first shock for any reason by 48%. Furthermore, sotalol reduced the probability 
of the delivery of an appropriate first ICD shock or a first shock of any reason (Pacifico, 
1999). Sotalol also prevented the occurrence of shocks in response to supraventricular 
arrhythmias, a frequent cause of inappropriate defibrillator therapy. Despite these beneficial 
effects, drug efficacy depends on patient compliance. In particular, if a lifetime therapy is 
required and is associated with side effects, this may lead to a discontinuation of drugs 
therapy. Furthermore, antiarrhythmic drugs such as amiodarone may increase the 
defibrillation threshold (Hohnloser, 2006). Even if this may not play a significant role in the 
majority of patients with modern devices, it can be harmful in the individual patient. In a 
randomized clinical trial comparing cooled radiofrequency catheter ablation of ventricular 
tachycardia and drugs therapy, arrhythmic recurrences was significantly lower with cooled 
ablation than with drug therapy. (Epstein, 1998 ). 
Regarding catheter ablation procedural outcomes, multiple small series, single center of 
catheter ablation for ventricular tachycardia have reported freedom from recurrent 
ventricular tachycardia in 50-80% of patients over follow-up, which ranges from 6 to 18 
months. Long-term results are sparse, and completeness of reported follow-ups is 
sometimes suboptimal. Patients remained on antiarrhythmic drugs (amiodarone 94% and 
sotalol 5%) postprocedure and those with persistently inducible clinical ventricular 
tachycardia had shorter time to death, and shorter time to ventricular tachycardia 
recurrence and were the only patients with recurrence of ventricular tachycardia storm 
(Carbucicchio, 2008). 
3.2.2 The role of ventricular function 
In our experience, among the 66 patients referred to our clinic for radiofrequency catheter 
ablation of recurrent post infarction ventricular tachycardias, only 19 (29%) showed 
recurrences during a mean follow-up of 26 ± 12 months. This finding “per se” highlights the 
role of radiofrequency catheter ablation in the overall clinical management of recurrent post 
infarction ventricular tachycardias in patients with ICD. In addition, our findings stressed 
the role of poor left ventricular function as an independent predictor of recurrent ventricular 
tachycardia. Among patients with ejection fraction < 35%, 11 out of 25 (44%) still continued 
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to have ventricular tachycardia recurrences, independently of whether the ventricular 
tachycardia responsible for ICD therapies was inducible at the end of the procedure or not. 
Most clinical trials (Moss, 2004; Moss, 1996; Buxton, 1999; Bardy, 2005) testing the efficacy of 
antiarrhythmic versus ICD therapy have used the ejection fraction as the marker for 
advanced disease, with the qualifying criteria in the range of 30–40% or less. Interestingly, in 
the AVID trial (Domanski, 1999) a subgroup analysis suggested that there was no benefit of 
ICD therapy over amiodarone for patients with ejection fraction between 36% and 40%, 
being all the benefit accrued to those patients with ejection fraction 35% or less. This 
observation raises the critical question we addressed in conceiving this study, about 
predictors of ventricular tachycardia recurrences, and consequently about therapeutic 
options, for patients with ejection fraction greater than 35%. Our findings show that, among 
patients with ejection fraction >35% and <50%, no recurrent ventricular tachycardia was 
further detected in the patients in whom the ventricular tachycardia responsible for ICD 
therapies was not inducible at the end of the procedure (100% specificity). Whereas 
ventricular tachycardia recurrences continued only in the patients, in whom the clinical 
ventricular tachycardia was inducible (100% sensitivity) (Colella, 2009). Actually, 
inducibility of the clinical ventricular tachycardia, more than being a predictor of ventricular 
tachycardia recurrences, is simply the consequence of radiofrequency catheter ablation 
failure (Della Bella, 2002), i.e. of the fact that the clinical ventricular tachycardia has not been 
successfully ablated. Accordingly, at least in patients with ejection fraction >35% and <50%, 
the procedure should be repeated until an acutely successful ablation of the clinical 
ventricular tachycardia is achieved. For these patients, indeed, radiofrequency catheter 
ablation might be considered a reasonable alternative to ICD as the first choice. Finally, our 
findings show that in all the 24 patients with ejection fraction >50% no recurrent ventricular 
tachycardia was any longer detected during the follow-up. Based upon our findings, a 
simple algorithm (Figure 3) is proposed for the management of recurrent ventricular  
 
 
Fig. 3. Algorithm for the management of recurrent Ventricular Tachycardias in patients with 
previous Myocardial Infarction.  
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tachycardias in patients with previous myocardial infarction: a) for patients with ejection 
fraction ≤35%, ICD still remains the first choice (class 1A). However, radiofrequency 
catheter ablation is indicated to reduce ICD shocks (class 1C) (Zipes, 2006), b) for patients 
with ejection fraction >35% and <50%, the first choice might be radiofrequency catheter 
ablation and any effort should be made to successfully ablate the VT, repeating the 
procedure if needed. The implantation of ICD might be limited to those patients in whom 
the ventricular tachycardia is not successfully ablated. c) For patients with EF ≥50%, the first 
choice might be radiofrequency catheter ablation. 
4. Conclusions 
In conclusion, the published studies have shown the important role of catheter ablation in 
patients with structural heart disease and ICD implantation who experienced appropriate 
ICD therapy due to recurrent ventricular tachycardias. Successful catheter ablation in these 
patients prevents or reduces the number of ventricular tachycardia recurrences as well as 
the rate of ICD shocks, improving the quality of life and probably long-term mortality. 
Finally, the question whether ablation can replace ICD in patients with structural heart 
disease is presented. The results of recently published studies are promising for further 
expansion of ventricular tachycardia ablation indication, but several points merit additional 
consideration. Catheter ablation of ventricular tachycardia is still an extremely complex 
procedure and the reported results reflect the outcome of such ablations from highly 
experienced and high-volume centers and, therefore, cannot be extrapolated to all 
electrophysiology departments without additional simplification and standardization of the 
ablation procedures and strategies. In spite of being able to achieve acute complete success 
in the majority of patients who underwent catheter ablation of ventricular tachycardia, 
accurate long-term prediction of outcome based on current risk predictors is difficult. 
Therefore, we cannot currently replace ICD with catheter ablation, although in selected 
patients, with hemodynamically stable and/or slow ventricular tachycardia and preserved 
or mildly reduced left ventricular function (for which data from randomized studies are 
lacking), catheter ablation might be considered an alternative to ICD. In addition, even upon 
developing more effective ablation strategies and finding good predictors of long-term 
outcome after a single center ablation procedure, the substrate of arrhythmia in patients 
with structural heart disease is dynamic. Due to this inherently dynamic characteristics of 
the arrhythmic substrate, cardioverter defibrillator implantation, cannot be replaced in the 
long-term, with catheter ablation of ventricular tachycardia. It is in fact necessary to stratify 
the risk repetitively and regularly, in order to perform repeated ablation procedures, if 
necessary. Thus, before widespread recommendation of catheter ablation of ventricular 
tachycardia becomes evident, especially prophylactic ablation, standardizing the ablation 
procedure and strategies, endpoints, and the follow-up should be performed. Further 
studies are necessary to clarify the role of catheter ablation of ventricular tachycardia on 
long-term mortality of patients with structural heart disease (Arya, 2009). ICD remains a 
life-saving device for patients with sustained ventricular tachycardia late after myocardial 
infarction; but in selected patients, especially in patients with ejection fraction > 30%, who 
are receiving an ICD for stable ventricular tachycardia, arrhythmic substrate ablation can be 
considered early. Evidence of a positive effect on survival, subsequent hospital admissions, 
or quality of life is needed before catheter ablation can be recommended for routine use. We 
believe that today’s trial is further evidence to support early use of catheter ablation, as a 
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valid alternative to antiarrhythmic drug therapy, for symptomatic recurrent ventricular 
tachycardia after ICD implantation, provided that expertise to safely perform the procedure 
is available (Stevenson, 2010). 
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